Rituximab: Mechanism of Action
Top Cited Papers
- 1 April 2010
- journal article
- review article
- Published by Elsevier in Seminars in Hematology
- Vol. 47 (2), 115-123
- https://doi.org/10.1053/j.seminhematol.2010.01.011
Abstract
No abstract availableKeywords
This publication has 74 references indexed in Scilit:
- Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo modelBlood, 2009
- Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2Blood, 2009
- A Polymorphism in the Complement ComponentC1qACorrelates with Prolonged Response Following Rituximab Therapy of Follicular LymphomaClinical Cancer Research, 2008
- Visualizing stromal cell dynamics in different tumor microenvironments by spinning disk confocal microscopyDisease Models & Mechanisms, 2008
- NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complementBlood, 2008
- Addition of fresh frozen plasma as a source of complement to rituximab in advanced chronic lymphocytic leukaemiaThe Lancet Oncology, 2007
- Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximabBlood, 2006
- Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic LeukemiaJournal of Clinical Oncology, 2005
- Rituximab-Mediated Sensitization of B-Non-Hodgkin's Lymphoma (NHL) to Cytotoxicity Induced by Paclitaxel, Gemcitabine, and VinorelbineCancer Biotherapy & Radiopharmaceuticals, 2002
- Mechanism of Cytotoxicity Induced by Chimeric Mouse Human Monoclonal Antibody IDEC-C2B8 in CD20-Expressing Lymphoma Cell LinesCellular Immunology, 2000